The cancer–natural killer cell immunity cycle

[1]  R. Weissleder,et al.  Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. , 2022, Immunity.

[2]  Ruijiang Li,et al.  Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. , 2020, JCI insight.

[3]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[4]  D. Raulet,et al.  NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists , 2020, Science Immunology.

[5]  D. Longo,et al.  Minimal PD-1 expression in mouse and human NK cells under diverse conditions. , 2020, The Journal of clinical investigation.

[6]  Laura F. Dagley,et al.  NK cell–derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS , 2020, The Journal of experimental medicine.

[7]  R. Negrin,et al.  Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion , 2020, Frontiers in Immunology.

[8]  Hai-hua Luo,et al.  Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. , 2020, The Journal of clinical investigation.

[9]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[10]  Melissa J. Davis,et al.  NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS , 2020, Frontiers in Immunology.

[11]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[12]  P. Duchateau,et al.  ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges , 2020, Nature Reviews Drug Discovery.

[13]  Ashley M. Laughney,et al.  Regenerative lineages and immune-mediated pruning in lung cancer metastasis , 2019, Nature Medicine.

[14]  Gavin D. Meredith,et al.  Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. , 2019, JCI insight.

[15]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[16]  Eric O Long,et al.  Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ , 2019, Front. Immunol..

[17]  S. Lorenz,et al.  Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity. , 2019, Cell reports.

[18]  E. Mazzon,et al.  Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets , 2019, Front. Oncol..

[19]  M. Gil,et al.  Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma , 2019, Journal of clinical medicine.

[20]  A. Santoni,et al.  Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention , 2019, Front. Immunol..

[21]  S. Loi,et al.  Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade , 2019, Clinical Cancer Research.

[22]  Y. Kaneda,et al.  NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis , 2019, Journal of Experimental & Clinical Cancer Research.

[23]  M. Maio,et al.  NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy , 2019, International journal of cancer.

[24]  R. Johnstone,et al.  Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. , 2019, Cell reports.

[25]  J. Settleman,et al.  Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance , 2019, bioRxiv.

[26]  Nikhil S. Joshi,et al.  Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation , 2019, Proceedings of the National Academy of Sciences.

[27]  K. Rezvani.  Adoptive cell therapy using engineered natural killer cells , 2019, Bone Marrow Transplantation.

[28]  E. Swisher,et al.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.

[29]  Nancy R. Zhang,et al.  Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade , 2019, Cell.

[30]  M. Altfeld,et al.  A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44 , 2019, Nature Immunology.

[31]  Ayham A. Zaitouny,et al.  Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment , 2019, Science Translational Medicine.

[32]  M. Caligiuri,et al.  Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion , 2019, Nature.

[33]  Athena W Wong,et al.  A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155 , 2019, Molecular & Cellular Proteomics.

[34]  C. Peano,et al.  Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors , 2019, Cell.

[35]  R. Eils,et al.  NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing , 2019, The Journal of experimental medicine.

[36]  G. Freeman,et al.  Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.

[37]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[38]  A. Roussel,et al.  Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity , 2019, Cell.

[39]  A. Pera,et al.  DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy , 2019, Cancers.

[40]  L. Ysebaert,et al.  Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes , 2019, Proceedings of the National Academy of Sciences.

[41]  K. Rezvani,et al.  The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[42]  Melissa J. Davis,et al.  A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients , 2019, Cancer Immunology Research.

[43]  L. Jia,et al.  Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT , 2019, OncoTargets and therapy.

[44]  Jing Wang,et al.  The deubiquitinase Otub1 controls the activation of CD8 T cells and NK cells by regulating IL-15-mediated priming , 2019, Nature Immunology.

[45]  Eric O Long,et al.  CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells , 2019, Cancer Immunology Research.

[46]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[47]  D. Campana,et al.  Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. , 2019, The Journal of clinical investigation.

[48]  J. Madore,et al.  CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function , 2019, Cancer Immunology Research.

[49]  M. Merad,et al.  Host tissue determinants of tumour immunity , 2019, Nature Reviews Cancer.

[50]  J. Orange,et al.  Interaction between nectin-1 and the human natural killer cell receptor CD96 , 2019, PloS one.

[51]  P. Vaupel,et al.  Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study , 2019, Strahlentherapie und Onkologie.

[52]  J. Winter,et al.  Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL , 2019, Cancer Immunology Research.

[53]  Joseph Cursons,et al.  The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. , 2019, Trends in immunology.

[54]  I. Amit,et al.  Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma , 2019, Cell.

[55]  O. Lantz,et al.  IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation , 2019, Cancer Immunology Research.

[56]  Figen Beceren-Braun,et al.  IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses , 2018, Proceedings of the National Academy of Sciences.

[57]  John T. Poirier,et al.  NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.

[58]  A. Gonzalez-Perez,et al.  NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival , 2018, Clinical Cancer Research.

[59]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[60]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[61]  M. Welters,et al.  NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines , 2018, Cell.

[62]  J. Madore,et al.  Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients , 2018, Oncoimmunology.

[63]  Laura F. Dagley,et al.  Therapeutic blockade of activin-A improves NK cell function and antitumor immunity , 2019, Science Signaling.

[64]  S. Quezada,et al.  Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming. , 2018, Cancer research.

[65]  M. McBurney,et al.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.

[66]  N. Huntington,et al.  Efficient genome editing of human natural killer cells by CRISPR RNP , 2018, bioRxiv.

[67]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[68]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[69]  D. Davis,et al.  Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells , 2018, The Journal of cell biology.

[70]  R. Sun,et al.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.

[71]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[72]  J. Walter,et al.  Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells , 2018, Nature Immunology.

[73]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[74]  Charles H. Yoon,et al.  Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity , 2018, Science.

[75]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[76]  Akiko Seki,et al.  Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells , 2018, The Journal of experimental medicine.

[77]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[78]  M. Caligiuri,et al.  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells , 2018, Nature Medicine.

[79]  A. Scope,et al.  NKp46 Receptor‐Mediated Interferon‐&ggr; Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis , 2018, Immunity.

[80]  B. Becher,et al.  Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade. , 2017, Cancer research.

[81]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[82]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[83]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[84]  C. Garlanda,et al.  IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity , 2017, Nature.

[85]  K. Rezvani,et al.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.

[86]  Deborah S. Barkauskas,et al.  Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. , 2017, Cancer research.

[87]  L. Galluzzi,et al.  Control of Metastasis by NK Cells. , 2017, Cancer cell.

[88]  N. Waddell,et al.  Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells , 2017, Nature Immunology.

[89]  C. Fan,et al.  Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. , 2017, Cancer research.

[90]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[91]  D. Olive,et al.  NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML , 2017, Oncoimmunology.

[92]  S. Eichmüller,et al.  Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system , 2017, PloS one.

[93]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[94]  Camille Guillerey,et al.  Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis , 2017, Oncoimmunology.

[95]  C. Watzl,et al.  LFA-1 Activation in NK Cells and Their Subsets: Influence of Receptors, Maturation, and Cytokine Stimulation , 2017, The Journal of Immunology.

[96]  A. Strasser,et al.  Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival , 2017, The Journal of experimental medicine.

[97]  A. Santoni,et al.  Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay , 2016, Journal of Hematology & Oncology.

[98]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[99]  A. Borczuk,et al.  HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status , 2016, Clinical Cancer Research.

[100]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[101]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[102]  I. Voskoboinik,et al.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing , 2016, Oncoimmunology.

[103]  Laura F. Dagley,et al.  CIS is a potent checkpoint in NK cell–mediated tumor immunity , 2016, Nature Immunology.

[104]  Chun Jimmie Ye,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells , 2016, Scientific Reports.

[105]  David K. Finlay,et al.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway , 2016, Science Signaling.

[106]  G. Belz,et al.  Innate lymphoid cells: parallel checkpoints and coordinate interactions with T cells. , 2016, Current opinion in immunology.

[107]  W. Shi,et al.  The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15. , 2016, Immunity.

[108]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[109]  I. Malanchi,et al.  Neutrophils support lung colonization of metastasis-initiating breast cancer cells , 2015, Nature.

[110]  A. Cesano.  nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA) , 2015, Journal of Immunotherapy for Cancer.

[111]  R. Sun,et al.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6* , 2015, The Journal of Biological Chemistry.

[112]  Ming-Ru Wu,et al.  B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity , 2015, The Journal of Immunology.

[113]  Benjamin G. Gowen,et al.  A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection , 2015, Science.

[114]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[115]  R. Childs,et al.  CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo , 2015, Cancer Immunology, Immunotherapy.

[116]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  A. Strasser,et al.  Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells , 2014, Nature Communications.

[118]  P. Altevogt,et al.  Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. , 2014, Cancer research.

[119]  A. Porgador,et al.  An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities , 2014, Oncotarget.

[120]  F. Souza-Fonseca-Guimaraes,et al.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions , 2014, Nature Immunology.

[121]  M. Speicher,et al.  Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients , 2014, Science Translational Medicine.

[122]  É. Vivier,et al.  Natural cytotoxicity receptors and their ligands , 2014, Immunology and cell biology.

[123]  Sonja Textor,et al.  Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. , 2013, Blood.

[124]  D. Chaussabel,et al.  Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. , 2013, Blood.

[125]  J. Taube,et al.  B7-H5 costimulates human T cells via CD28H , 2013, Nature Communications.

[126]  X. Zang,et al.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function , 2013, Proceedings of the National Academy of Sciences.

[127]  S. Gasser,et al.  Regulation of ligands for the NKG2D activating receptor. , 2013, Annual review of immunology.

[128]  Sumati Rajagopalan,et al.  Controlling natural killer cell responses: integration of signals for activation and inhibition. , 2013, Annual review of immunology.

[129]  Ming-Ru Wu,et al.  An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo , 2012, The Journal of Immunology.

[130]  Mark J. Smyth,et al.  Cancer immunoediting by the innate immune system in the absence of adaptive immunity , 2012, The Journal of experimental medicine.

[131]  N. Stanietsky,et al.  Recognition and Prevention of Tumor Metastasis by the NK Receptor NKp46/NCR1 , 2012, The Journal of Immunology.

[132]  Govind Bhagat,et al.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.

[133]  J. Gerring.  A case study , 2011, Technology and Society.

[134]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[135]  Eric O Long,et al.  Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. , 2010, Immunity.

[136]  F. Christiansen,et al.  Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. , 2009, Current opinion in immunology.

[137]  M. Caligiuri,et al.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. , 2009, Blood.

[138]  D. Raulet,et al.  Oncogenic stress sensed by the immune system: role of natural killer cell receptors , 2009, Nature Reviews Immunology.

[139]  Eric Vivier,et al.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans , 2009, The Journal of experimental medicine.

[140]  P. Mathew,et al.  Functional role of human NK cell receptor 2B4 (CD244) isoforms , 2009, European journal of immunology.

[141]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[142]  N. Sion-Vardy,et al.  Expression of ligands to NKp46 in benign and malignant melanocytes. , 2008, The Journal of investigative dermatology.

[143]  N. Huntington,et al.  Developmental pathways that generate natural-killer-cell diversity in mice and humans , 2007, Nature Reviews Immunology.

[144]  Todd A Fehniger,et al.  Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. , 2007, Immunity.

[145]  J. Trowsdale,et al.  Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. , 2007, Blood.

[146]  T. Spies,et al.  Promoter Region Architecture and Transcriptional Regulation of the Genes for the MHC Class I-Related Chain A and B Ligands of NKG2D1 , 2007, The Journal of Immunology.

[147]  M. Caligiuri,et al.  Human natural killer cell development , 2006, Immunological reviews.

[148]  Daniel M. Davis,et al.  Segregation of HLA-C from ICAM-1 at NK Cell Immune Synapses Is Controlled by Its Cell Surface Density1 , 2006, The Journal of Immunology.

[149]  C. Watzl,et al.  CD48 Stimulation by 2B4 (CD244)-Expressing Targets Activates Human NK Cells1 , 2006, The Journal of Immunology.

[150]  W. Yokoyama,et al.  How do natural killer cells find self to achieve tolerance? , 2006, Immunity.

[151]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[152]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[153]  M. Colonna,et al.  Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155) , 2004, The Journal of Immunology.

[154]  R. Goldfarb,et al.  2B4(CD244)-mediated activation of NK cells reduces metastases of B16F10 melanoma in mice. , 2003, Anticancer research.

[155]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[156]  M. Caligiuri,et al.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. , 2003, Blood.

[157]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[158]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[159]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[160]  S. Riddell,et al.  Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells , 2001, Nature Immunology.

[161]  T. Mcclanahan,et al.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. , 2000, Immunity.

[162]  S. Tangye,et al.  2B4-mediated activation of human natural killer cells. , 2000, Molecular immunology.

[163]  M. Llano,et al.  NK cell recognition of non-classical HLA class I molecules. , 2000, Seminars in immunology.

[164]  S. Tangye,et al.  The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. , 2000, Seminars in immunology.

[165]  R. Biassoni,et al.  Molecular Cloning of NKp46: A Novel Member of the Immunoglobulin Superfamily Involved in Triggering of Natural Cytotoxicity , 1998, The Journal of experimental medicine.

[166]  L. Moretta,et al.  NKp44, a Novel Triggering Surface Molecule Specifically Expressed by Activated Natural Killer Cells, Is Involved in Non–Major Histocompatibility Complex–restricted Tumor Cell Lysis , 1998, The Journal of experimental medicine.

[167]  Jun Wu,et al.  Association of DAP12 with activating CD94/NKG2C NK cell receptors. , 1998, Immunity.

[168]  S. Bauer,et al.  Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. , 1998, Science.

[169]  Eric Vivier,et al.  Inhibition of antigen‐induced T cell response and antibody‐induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP‐1 and SHP‐2 protein‐tyrosine phosphatases , 1998, European journal of immunology.

[170]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[171]  T. Mcclanahan,et al.  DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.

[172]  J. Ritz,et al.  T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules. , 1988, Journal of immunology.

[173]  J. C. Pratt,et al.  Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein , 1985, Nature.

[174]  Lingyun Wu,et al.  Neutrophils in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[175]  F. Aversa,et al.  The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. , 2019, Lung cancer.

[176]  Deborah S. Barkauskas,et al.  A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. , 2018, Cancer research.

[177]  Eric O Long,et al.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.

[178]  T. Lindahl,et al.  Repair of endogenous DNA damage. , 2000, Cold Spring Harbor symposia on quantitative biology.

[179]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.